South Africa has reached a historic milestone with the launch of clinical trials for its first locally manufactured cholera vaccine. This marks a giant leap towards vaccine independence and bolstering Africa’s health security.
Significant advancement in local manufacturing
Biovac, in collaboration with the South African Medical Research Council, started the vaccine trials at the Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital in Soweto. This marks the transition of Biovac from a vaccine distributor to a full-scale developer and manufacturer.
Building on years of innovation, the moment underscores South Africa’s commitment to tackling health challenges. These challenges include cholera outbreaks while reducing dependency on external suppliers. The country’s first Oral Cholera Vaccine (OCV-S) is being developed locally. This sets new benchmarks for scientific and healthcare leadership within Africa.
Collaborative backing and global support
The success of this initiative is attributed to Biovac’s tech-transfer partnership with the International Vaccine Institute (IVI). Backed by partners such as the Gates Foundation, Wellcome Trust, and Open Philanthropy, these clinical trials highlight the power of international and communal unity.
At the vaccine trial launch event, esteemed leaders, including South Africa’s Health Minister Dr Aaron Motsoaledi, expressed their optimism. Dr Morena Makhoana, CEO of Biovac, called the achievement a symbol of “hope, resilience, and Africa’s ability to protect itself”.
Major goals and prospects
With cholera continuing to devastate vulnerable populations, this locally manufactured vaccine comes as an essential tool to combat outbreaks. The African Union’s goal to produce 60% of Africa’s vaccines by 2030 becomes closer to reality with steps like these.
The trials will assess the vaccine’s effectiveness in reducing cholera cases, with Phase 1 demonstrating safety results. If all milestones are reached, the vaccine might be rolled out by 2028, addressing notable global cholera vaccine shortages.
Celebrating African innovation
South Africa’s investment in vaccine production showcases its leadership in innovation. Not only does this achievement strengthen Africa’s healthcare infrastructure, but it also reinvigorates faith in joint efforts, scientific excellence, and the local manufacturing of life-saving solutions.
